Literature DB >> 10626146

Amyloidosis.

M A Gertz1, M Q Lacy, A Dispenzieri.   

Abstract

Amyloidosis is considered rare but has an incidence similar to that of Hodgkin's disease and chronic granulocytic leukemia. The diagnosis should be considered in any patient with unexplained nephrotic-range proteinuria, heart failure, peripheral neuropathy, or hepatomegaly. If a monoclonal protein is found in a patient with any of these clinical presentations, a biopsy should be performed and the specimen stained with Congo red. The simplest source of diagnostic material is subcutaneous fat tissue. Treatment usually consists of chemotherapy, which may be oral and low dose or high dose with stem cell rescue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626146     DOI: 10.1016/s0889-8588(05)70122-2

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  32 in total

1.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Authors:  Vaishali Sanchorawala
Journal:  Am J Blood Res       Date:  2012-01-01

3.  Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Amyloid       Date:  2010-09       Impact factor: 7.141

4.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.

Authors:  Richard W McLaughlin; Janelle K De Stigter; Laura A Sikkink; Elizabeth M Baden; Marina Ramirez-Alvarado
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

5.  Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.

Authors:  Roshini S Abraham; Michelle K Manske; Neta S Zuckerman; Abhishek Sohni; Hanna Edelman; Gitit Shahaf; Michael M Timm; Angela Dispenzieri; Morie A Gertz; Ramit Mehr
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

6.  The value of conventional echocardiographic and tissue doppler imaging in the diagnosis of cardiac amyloidosis.

Authors:  Li Zhang; Mingxing Xie; Xinfang Wang; Yali Yang; Junhong Huang; Ming Cheng; Feixiang Xiang; Qing Lü
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

7.  Congestive heart failure: a case of protein misfolding.

Authors:  Chung-Eun Ha; Nadhipuram V Bhagavan; Miki Loscalzo; Stephen K Chan; Huy V Nguyen; Carlos N Rios; Stacey A A Honda
Journal:  Hawaii J Med Public Health       Date:  2014-06

8.  85-year-old man with epistaxis.

Authors:  Matthew J Butts; Joseph H Skalski; Christopher M Wittich
Journal:  Mayo Clin Proc       Date:  2011-04       Impact factor: 7.616

Review 9.  Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management.

Authors:  Jerry D Estep; Arvind Bhimaraj; A M Cordero-Reyes; Brian Bruckner; Matthias Loebe; Guillermo Torre-Amione
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

10.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.

Authors:  J Malcom; O Arnold; Jonathan G Howlett; Anique Ducharme; Justin A Ezekowitz; Martin J Gardner; Nadia Giannetti; Haissam Haddad; George A Heckman; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.